Цереброваскулярная болезнь: фармакологические свойства и эффективность дипиридамола как препарата с плейотропным механизмом действия


В.В. Чельцов, А.И. Мартынов

1 ФГАОУ ВО «Российский университет дружбы народов», Медицинский институт, г. Москва; 2 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, г. Москва
Рассмотрены основные клинико-фармакологические эффекты дипиридамола в контексте его применения при цереброваскулярной болезни. Сделан акцент на вазодилатирующем действии препарата, его способности улучшать перфузию тканей и антиоксидантном эффекте. Приведены результаты экспериментальных и клинических исследований, отражающих эффективность и безопасность дипиридамола. Отмечен плейотропный механизм действия препарата, позволяющий достичь комплексного воздействия на патогенетические факторы цереброваскулярной болезни.
Ключевые слова: дипиридамол, плейотропные эффекты, антиагреганты
Полный текст статьи доступен
в "Библиотеке Врача"

Литература

  • Fratiglioni L., Launer L.J., Andersen K. еt al. Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group // Neurology. 2000. Vol. 54. № 11. Suppl. 5. P. 10–15.
  • Aktas B., Utz A., Hoenig-Liedl P. Dipyridamole enhances NO/ cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies // Stroke. 2003. Vol. 34. № 3. P. 764–769
  • Chakrabarti S., Freedman J.E. Dipyridamole, cerebrovascular disease, and the vasculature // Vascul. Pharmacol. 2008. Vol. 48. № 4–6. P. 143–149.
  • The Dutch TIA Trial Study Group, van Gijn J., Algra A., Kappelle J., Koudstaal P.J., van Latum A. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N. Engl. J. Med. 1991;325:1261-6.
  • Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
  • Diener H.C., Bogousslavsky J., Brass L.M., Cimminiello C., Csiba L., Kaste M., Leys D., Matias-Guiu J., Rupprecht H.J., for the MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischemic stroke or transient ischemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial. Lancet. 2004:364,331-7.
  • Bhatt D.L., Fox K.A., Hacke W., Berger P.B., Black H.R., Boden W.E., Cacoub P., Cohen E.A., Creager M.A., Easton J.d., Flather M.D., Haffner S.M., Hamm C.W., Hankey G.J., Johnston S.C., Mak K.H., Mas J.L., Montalescot G., Pearson T.A., Steg P.G., Steinhubl S.R., Weber M.A., BrennanD.M., Fabry-Ribaudo L., Booth J., Topol E.J., for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 2006;354:1706-17.
  • Diener H.C., Cunha L.,Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 1999;143:1-13.
  • Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A. ESPRIT study group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367:1665-73.
  • Picano E. Dipyridamole-echocardiography test: the historical background and the physiologic basis. Eur. Heart J. 1989;10:365-76.
  • Stewart R.B., Marks R.G., Padgett P.D., Hale W.E. A longitudinal evaluation of dipyridamole drug use in an ambulatory elderly population. Chest. 1995;107:1049-52.
  • Gibbs C.R., Lip G.Y. Do we still need dipyridamole? Br. J. Clin. Pharmacol. 1998;45:323-8.
  • Best L.C., McGuire M.B., Jones P.B., Holland T.K., Martin T.J., Preston F.E., Segal D.S., Russell R.G. Mode of action of dipyridamole on human platelets. Thromb. Res.1979;16:367-79.
  • Dresse A., Chevolet C., Delapierre D., Masset H., Weisenberger H., Bozler G., Heinzel G. pharmacokinetics of oral dipyridamole (Persantin) and its effect on platelet adenosine uptake in man. Eur. J. Clin. Pharmacol. 1982;23:229-34.
  • German D.C., Kredich N.M., Bjornsson T.D. Oral dipyridamole increase plasma adenosine levels in human beings. Clin. Pharmacol. Ther. 1989;45:80-4.
  • Mills D.C., Smith J.B. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3’:5’-cyclic monophosphate in platelets. Biochem. J. 1971;121:185-96.
  • Gresele P., Zoya C., Deckmyn H., Arnout J., Vermylen J., Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb. Haemost. 1983;50:852-6.
  • Gresele P., Arnout J., Deckmyn H., Vermylen L. Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity. Thromb. Haemost.1986;55:12-8.
  • Blass K.E., Block H.U., Forster W., Ponicke K. Dipyridamole: a potent stimulator of prostacyclin (PGI2) biosynthesis. Br. J. Pharmacol. 1980;68:71-3.
  • Moncada S., Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet.1978;1(8077):1286-9.
  • Akhtar M., Ordovas K., Martin A., Higgins C.B., Michaels A.D. Effect of chronic sustained-release dipyridamole on myocardial blood flow and left ventricular function in patients with ischemic cardiomyopathy. Congest. Heart Fail. 2007;13:130-5.
  • Fryer R.M., Auchampach J.A., Gross G.J. Therapeutic receptor targets of ischemic preconditioning. Cardiovasc. Res. 2002;55:520-5.
  • Roy-Chaudhury P., Kelly B.S., Miller A., Reaves A., Armstrong J., Nanayakkara N., Heffelfinger S.C. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. Kidney Int. 2001;59:2325-34.
  • Thyberg J. Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. Histol. Histopathol. 1998;13:871-91.
  • Himmelfarb J., Couper L. Dipyridamole inhibits PDGF- and bFGF-induced vascular smooth muscle cell proliferation. Kidney Int. 1997;52:1671-7.
  • Hewitson T.D., Tait M.G., Kelynack K.J., Martic M., Becker G.J. Dipyridamole inhibits in vitro renal fibroblast proliferation and collagen synthesis. J. Lab. Clin. Med. 2002;140:199-208.
  • Zhuplatov S.B., Masaki T., Blumental D.K., Cheung A.K. Mechanism of dipyridamole’s action in inhibition of venous and arterial smooth muscle cell proliferation. Basic Clin. Pharmacol. Toxicol. 2006;99:431-9.
  • Rybalkin S.D., Bornfeldt K.E. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation. Thromb. Haemost. 1999;82:424-34.
  • Maurice D.H., Palmer D., Tilley D.G., Dunkerley H.A., Netherton S.J. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol. Pharmacol. 2003;64:533-46.
  • Criqui M.H., Langer R.D., Fronek A., Feigelson H.S., Klauber M.R., Browner D., McCann T.J. Mortality over a period of 10 years in patients with peripheral arterial disease. N. Engl. J. Med. 1992;326:381-6.
  • Venkatesh P.K., Pattillo Ch.B., Branch B., Hood J., Thoma S., Illum S., Pardue S., Teng X., Patel R.P., Kevil C.G. Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway. Cardiovasc. Res. 2010;85:661-70.
  • Lecas M., Lecas P., Latter D.A., Kutryk M.B., Stewart D. Growth factor-induced therapeutic neovascularization for ischemic vascular disease: time for a re-evaluation? Curr. Opin. Cardiol. 2006;21:376-84.
  • Lombardi F., Rambaldi R. Coronary angiogenesis: dipyridamole is back on stage? Eur. Heart J. 2001;22:1151-3.
  • Pattillo C.B., Bir S.C., Branch B.G., Greber E., Shen X., Pardue S., Patel R., Kevil C.G. Dipyridamole reverses peripheral ischemia and induces angiogenesis in the Db/Db diabetic mouse hind limb model by decreasing oxidative stress. Free Radic. Biol. Med. 2011;50(2):262-9.
  • Iuliano L., Pedersen J.Z., Rotilio G., Ferro D., Violi F. A potent chain-breaking antioxidant activity of the cardiovascular drug dipyridamole. Free Radic. Biol. Med. 1995;18:239-47.
  • Iuliano L., Colavita A.R., Camastra C., Bello V., Quintarelli C., Alessandroni M., Piovella F., Violi F. Protection of low density lipoprotein oxidation at chemical and cellular level by the antioxidant drug dipyridamole. Br. J. Pharmacol. 1996;119:1438-46.
  • Kusmic C., Picano E., Busceti C.L., Petersen C., Barsacchi R. The antioxidant drug dipyridamole spares the vitamin E and thiols in red blood cells after oxidative stress. Cardiovasc. Res. 2000;47:510-4.
  • Chakrabarti S., Vitseva O., Iyu D., Varghese S., Freesman J.E. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J. Pharmacol. Exp. Ther. 2005;315:494-500.
  • Guo Sh., Stins M., Ning M., Lo E.H. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc. Dis. 2010;30:290-6.
  • Ramakers B.P., Riksen N.P., Stal Th.H., Heemskerk S., van den Broek P., Peters W.H.M., van der Hoeven J.G., Smits P., Pickkers P. Dipyridamole augments the anti-inflammatory response during human endotoxemia. Critical Care. 2011;15:R289.
  • Weyrich A.S., Denis M.M., Kuhlmann-Eyre J.R., Spencer E.D., Dixon D.A., Marathe G.K., McIntyre T.M., Zimmermann G.A., Prescott S.M. Dipyridamole selectively inhibits inflammatory gene expression in platelet-monocyte aggregates. Circulation. 2005;111: 633-42.
  • Hallevi H., Hazan-Halevy I., Paran E. Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. Eur. J. Neurol. 2007;14:1002-7.
  • Coeugniet E., Bendtzen K., Bendixen G. Leucocyte migration inhibitory activity of concanavalin-A-stimulated human lymphocytes. Modification by dipyridamole, lysine-acetylsalicylate and heparin. Acta Med. Scand.1976;199:99-104.
  • Dong H., Osmanova V., Epstein P.M., Brocke S. Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes. Biochem. Biophys.Res. Commun. 2006;345:713-9.
  • Kim H.H, Liao J.K. Translation therapeutics of dipyridamole. Atheroscler. Thromb.Vasc. Biol.,2008;28(3):39-42.
  • Sacks H.S., Berner J., Nagalingham R., Chalmers T.C. Dipyridamole in the treatment of angina pectoris: a meta-analysis. Thromb. Res. Suppl. 1999;12:35-42.
  • Picano E., PISA (Persantin in Stable Angina) group. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study. Eur. Heart J. 2001;22(19):1785-93.
  • Gresele P., Momi S., Falcinelli E. Antiplatelet therapy: phosphodiesterase inhibitors. Br. J. Clin. Pharmacol. 2011;72(4):634-46.
  • Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M., Howard V., Kissela B., Kittner S., Lloyd-Jones D., McDermott M., Meigs J., Moy C., Nichol G., O’Donnell C.J., Roger V., Rumsfeld J., Sorlie P., Steinberger J., Thom T., Wasserthiel-Smoller S., Hong Y.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics — 2007 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115(5):e69–171.
  • Johnston S.C., Rothwell P.M., Nguyen-Huynh M.N., Giles M.F., Elkins J.S., Bernstein A.L., Sidney S. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369(9558):283-92.
  • Rothwell P.M., Giles M.F., Chandratheva A., Marquardt L., Geraghty O., Redgrave J.N., Lovelock C.E., Binney L.E., Bull L.M., Cuthbertson F.C., Welch S.J., Bosch S., Alexander F.C., Silver L.E., Gutnikov S.A., Mehta Z. Early use of Existing Preventive Strategies for Stroke (EXPRESS) study. Lancet. 2007;370(9596):1432-42.
  • Barnett H.J.M. Four decades of stroke prevention trials. Stroke. 2014;45:e59-62.
  • Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., Lowenthal A. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 1996;143(1–2):1–13.
  • Halkes P.H., van Gijn J., Kappelle L.J., Koudstaal P.J., Algra A., ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomized controlled trial. Lancet. 2006;367:1665-73.
  • Diener H.C., Sacco R.L., Yusuf S., Cotton D., Ounpuu S., Lawton W.A., Palesch Y., Martin R.H., Albers G.W., Bath P., Bornstein N., Chan B.P., Chen S.T., Cunha L., Dahlof B., De Keyser J., Donnan G.A., Estol C., Gorelick P., Gu V., Hermansson K., Hilbrich L., Kaste M., Lu C., Machnig T., Pais P., Roberts R., Skvortsova V., Teal P., Toni D., VanderMaelen C.,Voigt T.,Weber M., Yoon B.W. Prevention regimen for effectively avoiding second stroke (PRoFESS) study group. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Stroke (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7:875-84.
  • Antithrombotiс Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br. Med. J. 2002;324:71-86.
  • Leonardi-Bee J., Bath P.M., Bousser M.G., Davalos A., Diener H.C., Guiraud-Chaumeil B., Sivenius J., Yatsu F., Dewey M.E., on behalf of the Dipyridamole in Stroke Collaboration (DISC). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke. 2005;36:162-8.
  • Gorelic P.B. Stroke prevention. Arch.Neurol.1995;52:347-55.
  • Collins R., MacMahon S. Blood pressure, antihypertensive drug treatment and risk of stroke and of coronary heart disease. Br. Med. Bull. 1994;50:272-29.
  • Katsanos A.H., Filippatou A., Manios E., Deftereos S., Parissis J., Frogoudaki A., Vrettou A.R., Ikonomidis I., Pikilidou M., Kargiotis O., Voumvourakis K., Alexandrov A.W., Alexandrov A.V., Tsivgoulis G. Blood Pressure Reduction and Secondary Stroke Prevention. A Systematic Review and Metaregression Analysis of Randomized Clinical Trials. Hypertension. 2017;69:171-9.
  • De Schryver E.L., Algra A., van Gijn J., Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. An update. Stroke. 2008;39:1397-8.


    • Об авторах / Для корреспонденции

    Виктор Владимирович Чельцов, д.м.н., профессор кафедры общей и клинической фармакологии Медицинского института ФГАОУ ВО «Российский Университет дружбы народов». Адрес: 117198, г. Москва, ул. Миклухо-Маклая, д. 10, кор. 1. Тел.: (499) 787-38-03. E-mail: vcheltsov@mail.ru

    Анатолий Иванович Мартынов, д.м.н., профессор, академик РАН, профессор кафедры госпитальной терапии № 1 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России. Адрес: 127473, г. Москва, ул. Делегатская, д. 20, стр. 1. Тел.: (495) 609-67-00


    Похожие статьи

    К содержанию номера

    Бионика Медиа